Big Selloff on Wall Street as Stocks Plummet on Fed Jitters
at The Street - Wed Mar 25, 3:27PM CDT
Wednesday was a kick-you-in-the-guts kind of day.
MU: 26.68 (+0.01), XOM: 85.63 (+2.05), IBB: 351.32 (+3.86), KRFT: 90.61 (+1.51), SOXX: 95.09 (+1.20), KFX: 10.95 (+0.03), NVDA: 21.47 (+0.09), RDS.A: 60.93 (+0.45), AMD: 2.70 (-0.02), ALXN: 180.26 (-0.33), NLNK: 56.40 (+4.14), BP: 39.84 (+0.23), ARIA: 8.56 (+0.17), CVX: 106.90 (+2.62), XLE: 78.04 (+1.64), LXK: 43.13 (-0.17)
Stocks Sell Off on Fed Jitters; Oil Rallies as Yemen Fights Intensify
at The Street - Wed Mar 25, 2:22PM CDT
Stocks are lower in a volatile trading session on Wednesday.
MU: 26.68 (+0.01), IBB: 351.32 (+3.86), KRFT: 90.61 (+1.51), SOXX: 95.09 (+1.20), KFX: 10.95 (+0.03), NVDA: 21.47 (+0.09), AMD: 2.70 (-0.02), ALXN: 180.26 (-0.33), NLNK: 56.40 (+4.14), ARIA: 8.56 (+0.17), BRK.A: 219,700.00 (+2,699.92), LXK: 43.13 (-0.17)
ARIAD Announces Dismissal of Shareholder Class Action Lawsuit in Federal District Court
Business Wire - Wed Mar 25, 8:28AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the United States District Court for the District of Massachusetts dismissed the shareholder class action lawsuit filed in late 2013 against the Company and certain of its officers, directors and underwriters in connection with the events leading up to the temporary suspension of the marketing and commercial distribution of Iclusig(R) (ponatinib) on October 31, 2013, and subsequent re-launch in January 2014 based on revised U.S. prescribing information and a risk evaluation and mitigation strategy.
ARIA: 8.56 (+0.17)
Ariad Pharmaceuticals Has Returned 20.9% Since SmarTrend Recommendation (ARIA)
Comtex SmarTrend(R) - Tue Mar 24, 9:29AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on December 22nd, 2014 at $7.12. In approximately 3 months, Ariad Pharmaceuticals has returned 20.93% as of today's recent price of $8.61.
ARIA: 8.56 (+0.17)
ARIAD and Medison Pharma Announce Approval of Iclusig (Ponatinib) in Israel
Business Wire - Tue Mar 24, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Medison Pharma Ltd, Israel's leading international marketing group for innovative pharmaceuticals, today announced that the Israeli Ministry of Health has granted regulatory approval for Iclusig(R) (ponatinib) in Israel for adult patients with:
ARIA: 8.56 (+0.17)
Look for Shares of Ariad Pharmaceuticals to Potentially Pullback after Yesterday's 4.42% Rise
Comtex SmarTrend(R) - Thu Mar 19, 4:37PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $8.57 to a high of $9.09. Yesterday, the shares gained 4.4%, which took the trading range above the 3-day high of $8.78 on volume of 8.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 8.56 (+0.17)
ARIAD Announces Presentations of Preclinical Data at American Association for Cancer Research Annual Meeting
Business Wire - Thu Mar 19, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced its schedule of preclinical data presentations to be made at the American Association for Cancer Research (AACR) Annual Meeting 2015, taking place Saturday, April 18 through Wednesday, April 22, 2015, in Philadelphia.
ARIA: 8.56 (+0.17)
22.1% Return Seen to Date on SmarTrend Ariad Pharmaceuticals Call (ARIA)
Comtex SmarTrend(R) - Mon Mar 16, 5:10PM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on December 22nd, 2014 at $7.12. In approximately 3 months, Ariad Pharmaceuticals has returned 22.12% as of today's recent price of $8.70.
ARIA: 8.56 (+0.17)
ARIAD Announces Dismissal of Shareholder Derivative Lawsuit in Federal District Court
Business Wire - Tue Mar 10, 3:20PM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) announced today that the United States District Court for the District of Massachusetts dismissed the shareholder derivative lawsuit filed in late 2013 against the Company and certain of its officers and directors in connection with the events leading up to the temporary suspension of the marketing and commercial distribution of Iclusig(R) (ponatinib) on October 31, 2013, and subsequent re-launch in January 2014 based on revised U.S. prescribing information and a risk evaluation and mitigation strategy.
ARIA: 8.56 (+0.17)
Critical Alerts For TASER International, Cisco Systems, Netflix, Ubiquiti Networks, Ariad Pharmaceuticals, Zoe's Kitchen, Opko Health, Groupon, Alliance Fiber Optic and Silver Wheaton Released By InvestorsObserver
PR Newswire - Tue Mar 10, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for TASR, CSCO, NFLX, UBNT, ARIA, ZOES, OPK, GRPN, AFOP and SLW.
ZOES: 32.92 (+0.50), NFLX: 422.57 (+7.80), UBNT: 29.99 (+0.82), OPK: 14.71 (+0.22), AFOP: 17.40 (+0.10), SLW: 19.22 (-0.40), ARIA: 8.56 (+0.17), GRPN: 7.43 (-0.18), TASR: 24.63 (+0.56), CSCO: 27.65 (+0.52)
Ariad Pharmaceuticals Shares Up 11.5% Since SmarTrend's Buy Recommendation (ARIA)
Comtex SmarTrend(R) - Mon Mar 09, 11:26AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on December 22nd, 2014 at $7.12. In approximately 3 months, Ariad Pharmaceuticals has returned 11.52% as of today's recent price of $7.94.
ARIA: 8.56 (+0.17)
Oncology Biotech Company Could Be on the Cusp of New PRP Drug for the Treatment and Prevention of Metastatic Cancer
ACCESSWIRE - Mon Mar 09, 9:37AM CDT
WINDSOR, ON / ACCESSWIRE / March 9, 2015 / The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known Biotech stocks, would like to announce some recent breakthroughs in the development of new cancer treatments, and the companies that play in the field.
BLUE: 123.89 (+9.48), BIIB: 431.62 (+1.75), GILD: 100.69 (-0.31), KITE: 59.98 (+0.20), ARIA: 8.56 (+0.17), CELG: 120.02 (+1.34)
Why Ariad Pharmaceuticals, Inc. Catapulted 26% Higher in February
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 05, 7:02AM CST
What: Shares of Ariad Pharmaceuticals , a biopharmaceutical company primarily focused on discovering therapies to treat cancer, catapulted higher by 26% in February, based on data from S&P Capital IQ , following the release of its...
ARIA: 8.56 (+0.17)
Early Briefing on Biotech Industry Stocks -- ARIAD Pharma, Array BioPharma, Rexahn Pharma, Inotek Pharma, and Neurocrine Biosciences
PR Newswire - Tue Mar 03, 7:40AM CST
Editor Note: For more information about this release, please scroll to bottom.
RNN: 0.72 (-0.01), NBIX: 41.53 (+2.75), ITEK: 5.19 (-0.40), ARIA: 8.56 (+0.17), ARRY: 7.54 (+0.14)
Uptrend Call Working As Ariad Pharmaceuticals Stock Rises 12.2% (ARIA)
Comtex SmarTrend(R) - Mon Mar 02, 9:55AM CST
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on December 22nd, 2014 at $7.12. In approximately 2 months, Ariad Pharmaceuticals has returned 12.22% as of today's recent price of $7.99.
ARIA: 8.56 (+0.17)
Seeking Alpha's Biotech Weekly: Achillion Overdone, Sanofi's Toujeo A Go, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
CYTK: 7.11 (-0.05), VRX: 201.38 (+3.54), ACT: 304.76 (+1.20), PCYC: 256.43 (-0.12), MDT: 78.42 (+1.04), CAH: 90.80 (+0.71), CLDX: 27.84 (+0.67), HSP: 87.72 (-0.16), AGN: 240.22 (+2.88), JNJ: 101.55 (+1.21), ATOS: 1.91 (+0.13), ONVO: 3.37 (-0.29), PTCT: 64.85 (+2.23), SNY: 50.24 (+0.27), PTLA: 38.50 (-0.16), INCY: 94.19 (-0.17), PFE: 35.00 (+0.47), CPHR: 9.45 (-0.43), MYL: 60.00 (-1.63), AMGN: 164.30 (+1.71), LLY: 73.87 (+0.29), BMY: 65.76 (+0.50), MNKD: 5.34 (+0.10), NKTR: 11.31 (+0.22), OMER: 22.39 (+0.53), DVA: 82.17 (+0.34), GILD: 100.69 (-0.31), SGEN: 36.10 (-0.12), ACHN: 10.24 (+0.08), MRK: 58.34 (+0.59), TEVA: 62.52 (+0.54), BIL: 45.71 (-0.01), ARIA: 8.56 (+0.17), NVS: 101.31 (+0.91)
What Sarissa Capital's Proxy Fight Means For Ariad Investors
Investing Healthcare - at Seeking Alpha - Mon Feb 23, 7:53AM CST
AMRN: 2.39 (-0.02), VVUS: 2.52 (-0.05), ARIA: 8.56 (+0.17)
Nasdaq stocks posting largest percentage increases
AP - Fri Feb 20, 5:00PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
PATK: 62.60 (unch), TILE: 20.59 (-0.02), DISCB: 31.38 (+0.01), DISCA: 31.09 (-0.18), CCRN: 12.17 (+0.18), EGLT: 13.09 (-0.43), DISCK: 29.79 (+0.02), PRQR: 24.35 (+1.05), AMOT: 33.20 (-0.67), ATRO: 72.78 (+0.71), ASMB: 13.03 (+0.15), ARIA: 8.56 (+0.17), UNTD: 15.99 (+0.32), WSCI: 5.98 (-0.02), SZMK: 7.40 (-0.13)
Most active Nasdaq-traded stocks
AP - Fri Feb 20, 5:00PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
MU: 26.68 (+0.01), FB: 83.19 (-0.11), DISCB: 31.38 (+0.01), DISCA: 31.09 (-0.18), INTC: 31.46 (-0.54), DISCK: 29.79 (+0.02), MRVL: 15.18 (-0.06), AMAT: 22.77 (-0.06), ODP: 9.35 (+0.11), ARIA: 8.56 (+0.17), MSFT: 40.96 (-0.01), ZNGA: 2.78 (+0.01), AAPL: 126.37 (+3.12), CSCO: 27.65 (+0.52)
Arista and Noodles are big market movers
AP - Fri Feb 20, 4:34PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
FUEL: 9.24 (-0.19), NDLS: 17.54 (-0.06), ARIA: 8.56 (+0.17)